Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 FY- Text added to 2022 FY
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
New words:
abnormal, accelerate, Activelle, Actrapid, Aeterna, appealed, appellate, authorisation, AWARDED, Beijing, biopharmaceutical, booster, category, ceased, cell, Christensen, Christina, Circuit, civil, complement, conflict, consideration, consumer, Court, criminal, Dahl, discretionary, dose, Elisabeth, energy, ERRONEOUSLY, essential, Estrofem, etavopivat, Forma, fully, grew, haemoglobin, Hyperoxaluria, Insulatard, invalidated, invalidation, IP, Jensen, Kliogest, LDHA, MacrilenTM, medium, Mette, Mixtard, Nedosiran, nonGMP, Novofem, NovoFine, NovoNorm, ongoing, overseeing, passed, prevalence, rare, recessionary, RECOVER, red, ROIC, SCD, sickle, siRNA, small, statute, stopped, technical, temporarily, transforming, transmission, twelve, Ukraine, unrest, Vagifem, VBP, war, Ziltivekimab
Removed:
achieved, added, analog, Anne, antibody, aspart, broadly, comparing, discount, Durham, event, exclusive, exercise, FDA, GHD, glargine, injection, IQVIA, Kverneland, labor, license, Marie, MAT, mealtime, mitigate, NBRx, NRDL, participation, planned, positive, premix, proposed, solid, soluble, stake, Stig, submitted, tablet, travel, treat, union, wide
Valuein 2021 FY filing- Value in 2022 FY filing
Original filings
Filing view